Key Differences When Switching From Mounjaro to Wegovy
Understanding the Switch: Mounjaro vs Wegovy Mechanisms
When switching from Mounjaro to Wegovy, it's essential to understand the key differences between these prescription-only medicines. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. This fundamental difference in mechanism may explain why some patients respond differently to each treatment when used alongside a reduced-calorie diet and increased physical activity.
The transition from Mounjaro's dual-action approach to Wegovy's single-pathway mechanism requires careful consideration by your prescriber. Both medications work on brain appetite centres to reduce hunger and promote feelings of fullness, but the additional GIP receptor activity in Mounjaro may provide different effects on glucose metabolism and satiety signals. Your clinical team at EverydayMeds can guide this transition based on your individual response and treatment goals.
Pricing Comparison for Switching From Mounjaro to Wegovy
Cost considerations often influence the decision when switching from Mounjaro to Wegovy. At EverydayMeds, Wegovy pens start at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers benefit from discount code FIRST40, whilst returning customers use DOSE25, both applied at checkout to reach these final prices.
Our bundle options provide convenient multi-month supplies for those committed to their weight management journey. The Intro Trio (0.25mg, 0.5mg & 1mg) costs £299.99, covering your first 12 weeks of treatment, whilst the Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 suits those requiring a different escalation pattern. For maintenance therapy, the Ultimate Stability Trio provides three 2.4mg pens for £649.99, ensuring uninterrupted treatment supply.
Clinical Evidence Supporting Wegovy vs Mounjaro Transitions
The STEP clinical trial programme demonstrates Wegovy's efficacy in weight management, with STEP 1 showing approximately 15% average weight loss at 68 weeks compared to 2.4% with placebo when used alongside lifestyle interventions. The recent SELECT cardiovascular outcomes trial revealed a 20% reduction in major cardiovascular events, adding important safety data for long-term use.
When considering switching from Mounjaro to Wegovy, it's important to note that direct head-to-head comparisons between trials aren't possible due to different study designs and patient populations. Both medications have demonstrated significant efficacy in clinical trials, and individual responses may vary based on personal factors, medical history, and treatment adherence patterns.
How Wegovy Works After Switching From Mounjaro
Wegovy's mechanism as a GLP-1 receptor agonist may provide a different experience compared to Mounjaro's dual-action approach. The medication works by mimicking incretin hormones that naturally regulate blood sugar and appetite, specifically targeting GLP-1 receptors in the brain's appetite control centres. This action helps reduce food cravings and promotes earlier feelings of fullness during meals, supporting portion control and reduced caloric intake. Unlike Mounjaro's additional GIP receptor activity, Wegovy focuses solely on the GLP-1 pathway, which may result in different side effect profiles or efficacy patterns. The once-weekly FlexTouch pen delivery system provides consistent medication levels throughout the week, maintaining steady appetite suppression effects. Your prescriber will determine the appropriate starting dose based on your previous Mounjaro experience and current clinical status.
Ordering Process for Wegovy After Mounjaro Experience
Switching from Mounjaro to Wegovy through EverydayMeds involves a comprehensive but streamlined process designed for your safety and convenience. Begin with our 3-minute online clinical assessment, which captures your medical history, current medications, and previous experience with weight management treatments including Mounjaro. Your information undergoes review by our qualified prescribers within 3 working days (or 24 hours with express service), who evaluate the appropriateness of transitioning to Wegovy based on your individual circumstances. Once approved, your Wegovy prescription ships via next-day delivery using temperature-controlled cold-chain logistics to maintain medication integrity. Our GPhC-registered pharmacy (#9012878) ensures all regulatory requirements are met throughout the prescribing and dispensing process. The entire journey from assessment to delivery typically completes within 4-5 working days, or 2 days with express prescriber review.
Storage Advantages When Moving From Mounjaro to Wegovy
One practical advantage when switching from Mounjaro to Wegovy involves storage flexibility, particularly important for frequent travelers or those with limited refrigerator space. Wegovy pens maintain potency for up to 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. Store unopened Wegovy pens in the refrigerator at 2-8°C until first use, then either continue refrigerated storage or keep at room temperature for the extended 6-week period. The FlexTouch pen system includes dose escalation from 0.25mg through 2.4mg over 16 weeks, with each pen providing 4 weekly injections at the prescribed dose level. Always protect pens from direct sunlight and extreme temperatures, and never freeze or shake the medication as this may affect its effectiveness.
Dose Transition Strategies for Switching From Mounjaro to Wegovy
The transition from Mounjaro to Wegovy requires careful dose management to minimise potential side effects whilst maintaining treatment efficacy. Wegovy follows a mandatory dose escalation schedule starting at 0.25mg weekly for the first month, regardless of your previous Mounjaro dose level. This cautious approach allows your system to adjust to semaglutide's different receptor activity pattern compared to tirzepatide's dual mechanism.
Your prescriber may recommend a specific transition timing, potentially including a washout period between stopping Mounjaro and starting Wegovy, depending on your individual clinical situation. The escalation continues through 0.5mg, 1mg, and 1.7mg doses before reaching the 2.4mg maintenance level at week 17, with each stage lasting 4 weeks to optimise tolerability and effectiveness.
Making Your Wegovy vs Mounjaro Decision
Both Wegovy and Mounjaro represent evidence-based approaches to prescription weight management, each offering unique advantages depending on individual patient factors and treatment responses. The decision to switch from Mounjaro to Wegovy should involve thorough discussion with your healthcare provider about your current treatment experience, side effect profile, and weight management goals. EverydayMeds stocks both medications, providing flexibility for your prescriber to recommend the most appropriate option based on your clinical needs rather than pharmacy availability constraints. Our clinical assessment process captures detailed information about your previous treatment experience, allowing for informed prescribing decisions and appropriate dose transition planning. Begin your assessment today at https://everydaymeds.co.uk/collections/weight-loss using discount code FIRST40 for new customers or DOSE25 for returning patients, with both codes applied at checkout to reach our competitive pricing structure.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
